|
|
News Breaks | | | | September 25, 2012 | | 08:05 EDT |  | ABT | Abbott launches Absorb BVS in international markets
Abbott announced today that Absorb, the world's first drug eluting bioresorbable vascular scaffold, or BVS, is now widely available across Europe and parts of Asia Pacific and Latin America. Absorb is a first-of-its-kind device for the treatment of coronary artery disease. The international launch of Absorb is supported by a robust clinical trial program that encompasses five studies in more than 20 countries around the world. Absorb is neither approved nor authorized for sale and currently is in development with no regulatory status in the United States. Absorb is authorized for sale in CE Mark countries. Absorb is now available in Europe, the Middle East, parts of Asia Pacific, including Hong Kong, Singapore, Malaysia and New Zealand, and parts of Latin America. | |
|
News For ABT From The Last 14 Days Check below for free stories on ABT the last two weeks. |
|
|
| May 22, 2013 | | 07:28 EDT |  | ABT | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link | | | May 21, 2013 | | 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
 Subscribe for More Information | | | May 20, 2013 | | 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. | |
|
|
|
|
|
|
